Wednesday, August 02, 2006
Favrille Selects Camstar’s MES for the Manufacture of Personalized Medicines in the Biotech Industry
Camstar, the leading provider of enterprise manufacturing execution and quality management solutions, announced today that Favrille, a biopharmaceutical company developing patient-specific cancer immunotherapies, has selected Camstar’s manufacturing execution system (MES), InSite, to replace the company’s current paper-driven batch records to streamline processes.
Favrille is currently in Phase III clinical trials for FavId®, an active immunotherapy for the treatment of follicular B-cell non-Hodgkin’s lymphoma. As the company moves toward commercialization of this product, it is focusing on the implementation of Electronic Batch Records to help scale manufacturing efforts.
Read The Complete Article >>
« Previous Page | pg 1 of 1 | Next Page »